Evidence mapPaperPMID 40500549Full record

ArticleDiscover oncology2025

Trends and visualization analysis of research on MASLD-Related hepatocellular carcinoma: a bibliometric analysis.

Hongkun Yin, Xusheng Zhang, Qi Wang

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hongkun Yin *Ningxia Medical University, Yinchuan, 750004, China.
Xusheng Zhang *Ningxia Medical University, Yinchuan, 750004, China.
Qi WangGeneral Hospital of Ningxia Medical University, Yinchuan, 750004, China. wq-6562@163.com.

Funding

Key Research and Development Program of Ningxia 2021BEG02038
6 · The paper itself

Abstract

BACKGROUND AND

objectivesMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is one of the leading causes of hepatocellular carcinoma (HCC). Over the years, significant progress has been made in diagnosing and treating MASLD. However, there is a lack of bibliometric analysis exploring the relationship between MASLD and HCC. This study aims to comprehensively analyze the knowledge structure and research status of MASLD-related HCC using bibliometric methods.

methodsThe study was conducted using the Web of Science Core Collection (WoSCC) database, retrieving literature related to MASLD and HCC from 2020 to 2024. VOSviewer, CiteSpace, and the R package "bibliometrics" were used for data analysis.

resultsThe study included 2,576 articles from 97 countries. The results showed that the number of publications related to MASLD and HCC increased steadily until 2023, after which there was a slight decline. China (The People's Republic of China) is the country with the highest volume of research output, while the United States is the country with the highest number of citations. The University of California System, the Chinese University of Hong Kong, and the Egyptian Knowledge Bank were the leading contributing institutions. The International Journal of Molecular Sciences, Cancers, and Liver International were the most influential journals in this field, with the International Journal of Molecular Sciences being the most co-cited journal, and the Journal of Hepatology had the highest local impact in the field, as evaluated by the H-index. The publications were authored by 13,851 researchers, with Vincent Wai-Sun Wong, Masato Yoneda, and Rohit Loomba being the most influential authors in the field of MASLD and HCC. Rohit Loomba and Hashem B. El-Serag were the most cited authors. Trend analysis indicated that "tissue", "element-binding protein", and "contributes" were the most frequently studied topics in 2024, suggesting emerging research trends.

conclusionThis study provides a comprehensive summary of the research trends and developments in HCC related to MASLD over the past five years. The findings reveal the latest research frontiers and hotspots in this field, offering valuable insights for future research. However, it should be noted that although the WoSCC is a widely recognized and authoritative database, it may have limitations related to regional bias, language coverage, and metadata accuracy, which could potentially affect the comprehensiveness of our analysis.

Indexed as

BibliometricsCiteSpaceHepatocellular carcinomaMASLDVOSviewer

Identifiers

PMID40500549
PMCPMC12158869

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.